Premium
Vascular regenerative therapies for the treatment of erectile dysfunction: current approaches
Author(s) -
Condorelli R. A.,
Calogero A. E.,
Vicari E.,
Favilla V.,
Morgia G.,
Cimino S.,
La Vignera S.
Publication year - 2013
Publication title -
andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.947
H-Index - 43
eISSN - 2047-2927
pISSN - 2047-2919
DOI - 10.1111/j.2047-2927.2013.00087.x
Subject(s) - erectile dysfunction , regenerative medicine , medicine , mesenchymal stem cell , stem cell therapy , endothelial dysfunction , transplantation , bioinformatics , stem cell , endothelial nitric oxide synthase , vascular endothelial growth factor , cgmp specific phosphodiesterase type 5 , adipose tissue , diabetes mellitus , intensive care medicine , nitric oxide , vegf receptors , nitric oxide synthase , pathology , endocrinology , biology , microbiology and biotechnology , enos
Summary The pharmacological treatment of erectile dysfunction ( ED ) is mainly represented by the administration of inhibitors of phosphodiesterase‐5 ( PDE 5). However, in the clinical practice many patients do not benefit from such a treatment, hence the scientific interest extends to other therapeutic strategies; in particular, to the vascular regenerative therapy. This review describes the main acquisitions related to this approach represented by the mesenchymal stem cell or adipose tissue stem cell transplantation and endothelial nitric oxide synthase or vascular endothelial growth factor gene therapy. Moreover, there are other two aspects of wide interest represented by the potential vascular regenerative effects exerted by the PDE 5 inhibitors and the therapeutic strategies for a category of patients who more frequently do not respond to the conventional treatment for ED , the patients with diabetes mellitus.